

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/841,580	04/24/2001	Andrea Califano	YOR920000687US2	5406
48062 RYAN, MASC	7590 06/26/2007 DN & LEWIS, LLP		EXAMINER	
1300 POST ROAD			CLOW, LORI A	
SUITE 205 FAIRFIELD, CT 06824			ART UNIT	PAPER NUMBER
			1631	
			MAIL DATE	DELIVERY MODE
			06/26/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	09/841,580	CALIFANO ET AL.			
Office Action Summary	Examiner	Art Unit			
	Lori A. Clow, Ph.D.	1631			
The MAILING DATE of this communication ap	1				
Period for Reply		•			
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailling date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION (136(a)). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 18 A	<u>pril 2007</u> .				
2a)⊠ This action is <b>FINAL</b> . 2b)□ This	•				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under I	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.			
Disposition of Claims					
4)⊠ Claim(s) <u>1-3,17-19,23-25 and 29</u> is/are pendir	ng in the application.				
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-3,17-19,23-25 and 29</u> is/are rejected	ed.	•			
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/o	or election requirement.				
Application Papers					
9) The specification is objected to by the Examine	er.				
10) ☐ The drawing(s) filed on is/are: a) ☐ acc		Examiner.			
Applicant may not request that any objection to the					
Replacement drawing sheet(s) including the correct	ction is required if the drawing(s) is ob	ojected to. See 37 CFR 1.121(d).			
11) ☐ The oath or declaration is objected to by the E	xaminer. Note the attached Office	e Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign	n priority under 35 U.S.C. § 119(a	i)-(d) or (f).			
a) All b) Some * c) None of:	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	, (-, -			
1. Certified copies of the priority documen	ts have been received.				
2. Certified copies of the priority documen	ts have been received in Applicat	ion No			
<ol><li>Copies of the certified copies of the price</li></ol>	ority documents have been receiv	ed in this National Stage			
application from the International Burea	,				
* See the attached detailed Office action for a list	of the certified copies not receive	ed.			
Attachment(s)	_				
1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary Paper No(s)/Mail D				
<ul> <li>2) Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>3) Information Disclosure Statement(s) (PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ul>	5) Notice of Informal F 6) Other:				

#### **DETAILED ACTION**

Applicants' response, filed 18 April 2007, has been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

Claims 1-3, 17-19, 23-25 and 29 are currently pending. Claims 4-16, 20-22 and 26-28 have been cancelled.

### Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-3, 17-19, 23-25, and 29 remain rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention, for the reasons set forth in the previous Office Action.

#### Response to Applicant's Arguments

1. Applicant argues that the specification teaches the SPLACH algorithm at page 15, lines 2-9 in response to the Examiner's rejection that the "specification fails to teach how to use transformed gene expression signals to determine gene expression patterns".

Art Unit: 1631

While it is acknowledged that the specification teaches the SPLASH algorithm, Applicant is arguing that the noted features upon which applicant relies (i.e., phenotype matrix, maximal patterns, submatrices) are not recited in the rejected claim(s). Applicant is reminded that although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Therefore, the claims, as written, are not enabled to perform the characterization of gene expression using the steps instantly claimed. The claims are not commensurate in scope with what is taught in the specification and therefore remain rejected fro lack of enablement.

2. Applicant argues that the claims have been amended to overcome the rejection pertaining to "the lack of enablement for the claims being drawn to characterizing gene expression of an unknown sample by comparison to gene expression patterns".

This is persuasive and the portion of the rejection pertaining to that statement is hereby withdrawn in view of the amendments to the claims clarifying that the expression signals comprise both control data and phenotype data.

#### Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-3, 17-19, 23-25, and 29 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. *This is a new rejection necessitated by amendment*.

Claims 1, 17, and 23 newly recite, "a plurality of gene expression signals for a gene are determined wherein the signals comprise control data and phenotype data". It is unclear what makes up the control data versus the phenotype data. Is the control data derived from healthy individuals/cells and the phenotype data derived from unhealthy individuals/cells, for example? Is the control data comprised of phenotype data from "normal" samples, for example? Clarification is requested.

Claims 1, 17, and 23 recite a "transforming" step. Since this step has been amended to read "in said control data" it is unclear as to what is intended by this step. Is the transformation ONLY done on the control data? Clarification is requested.

Claims 1, 17, and 23, as amended, recite "by searching said transformed gene expression signal for one or more gene expression patterns" to further clarify how the transformed signals are used. It is unclear how to "use" a transformed signal to determine patterns by searching the transformed signals. The step does not make sense. Clarification is requested.

Claims 1, 17, and 23, as amended, recite, "that characterize said control data and said phenotype data to characterize said unknown sample as either said control data or said phenotype data or neither". It is unclear how the unknown sample can be the control sample or the phenotype sample. Clarification is requested. Perhaps it is intended that the unknown sample be more similar to the control versus the phenotype data, for example. Clarification is requested.

## Conclusion

No claims are allowed.

Application/Control Number: 09/841,580

Art Unit: 1631

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

## **Inquiries**

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (See 37 CFR § 1.6(d)). The Central Fax Center Number is (571) 273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lori A. Clow, Ph.D., whose telephone number is (571) 272-0715. The examiner can normally be reached on Monday-Friday from 10 am to 6:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of

Art Unit: 1631

the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

June 13, 2007 Lori A. Clow, Ph.D. Primary Patent Examiner Art Unit 1631